Olanzapine polymorph crystal form

• US 5,736,541 A
• Filed: 07/25/1996
• Issued: 04/07/1998
• Est. Priority Date: 03/24/1995
• Status: Expired due to Term

• Current Assignee: Eli Lilly and Company, Lilly Industries Limited
• Original Assignee: Eli Lilly and Company
• Inventors: Bunnell, Charles Arthur, Larsen, Samuel Dean, Hendriksen, Barry Arnold
• Primary Examiner(s): Shah, Mukund J.
• Assistant Examiner(s): TRUONG, TAMTHOM NGO
• Application Number:
  US08/686,989
• Time in Patent Office: 621 Days
• Field of Search: 540/557, 514/220
• US Class Current: 514/220
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: C07D 495/04 Ortho-condensed systems

Abstract

The invention provides Form II, a pharmaceutically elegant, stable polymorph of olanzapine useful for treating a condition selected from the group consisting of a psychotic condition, mild anxiety and gastrointestinal conditions.

Claims

1. Form II olanzapine polymorph having a typical x-ray powder diffraction pattern as represented by the following interplanar spacings:

space="preserve" listing-type="tabular">______________________________________ d (Å

) ______________________________________ 10.2689 8.577 7.4721 7.125 6.1459 6.071 5.4849 5.2181 5.1251 4.9874 4.7665 4.7158 4.4787 4.3307 4.2294 4.141 3.9873 3.7206 3.5645 3.5366 3.3828 3.2516 3.134 3.0848 3.0638 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007. ______________________________________

2. Form II as claimed in claim 1 which is substantially pure.

3. Form II as claimed in claim 2 which contains less than about 5% Form I as hereinbefore defined.

4. Form II as claimed in claim 3 which contains less than about 2% content of Form I as hereinbefore defined.

5. Form II as claimed in claim 1 which is solvate free.

6. Form II as claimed in claim 2 which is anhydrous.

7. A pharmaceutical formulation comprising as an active ingredient Form II as claimed in claim 1 associated with one or more pharmaceutically acceptable carriers, excipients, or diluents therefor.

8. A pharmaceutical formulation as claimed in claim 7 which is a tablet.

9. A pharmaceutical formulation of claim 7 wherein the formulation is solvate free.

11. A method for treating a condition selected from the group consisting of a psychotic condition, mild anxiety and gastrointestinal conditions comprising administering an effective amount of Form II as claimed in claim 1 to a patient in need thereof.

12. A method of claim 11 wherein the condition is schizophrenia or a schizophreniform disorder.

13. A pharmaceutical formulation comprising as an active ingredient Form II as claimed in claim 2 associated with one or more pharmaceutically acceptable carriers, excipients, or diluents therefor.

14. A Form II olanzapine polymorph as claimed by claim 2 which contains less than about ten percent (10%) Form I olanzapine polymorph.

15. A Form II olanzapine polymorph as claimed by claim 2 which contains less than one half percent (0.5%) related substances.

16. A Form II olanzapine polymorph as claimed in claim 1 further characterized by substantially the following x-ray powder diffraction pattern wherein d represents the interplanar spacing and I/I₁ represents the typical relative intensities:

space="preserve" listing-type="tabular">______________________________________ d I/I.sub.1 ______________________________________ 10.2689 100.00 8.577 7.96 7.4721 1.41 7.125 6.50 6.1459 3.12 6.071 5.12 5.4849 0.52 5.2181 6.86 5.1251 2.47 4.9874 7.41 4.7665 4.03 4.7158 6.80 4.4787 14.72 4.3307 1.48 4.2294 23.19 4.141 11.28 3.9873 9.01 3.7206 14.04 3.5645 2.27 3.5366 4.85 3.3828 3.47 3.2516 1.25 3.134 0.81 3.0848 0.45 3.0638 1.34 3.0111 3.51 2.8739 0.79 2.8102 1.47 2.7217 0.20 2.6432 1.26 2.6007 0.77. ______________________________________

17. A Form II olanzapine polymorph as claimed by claim 16 which is substantially pure.

18. A Form II olanzapine polymorph as claimed by claim 17 which contains less than about 5% Form I olanzapine polymorph.

19. A Form II olanzapine polymorph as claimed by claim 16 which is solvate free.

20. A Form II olanzapine polymorph as claimed by claim 17 which is anhydrous.

21. A pharmaceutical formulation comprising as an active ingredient Form II olanzapine polymorph as claimed by claim 16 associated with one or more pharmaceutically acceptable carriers, excipients, or diluents therefor.

22. A method for treating a condition selected from the group consisting of a psychotic condition, mild anxiety and gastrointestinal conditions comprising administering an effective amount Form II olanzapine polymorph as claimed in claim 16 to a patient in need thereof.

23. A pharmaceutical formulation comprising as an active ingredient Form II olanzapine polymorph as claimed in claim 17 associated with one or more pharmaceutically acceptable carriers, excipients, or diluents therefor.

24. A Form II olanzapine polymorph as claimed by claim 17 which contains less than about ten percent (10%) Form I olanzapine polymorph.

25. A Form II olanzapine polymorph as claimed by claim 17 which contains less than one half percent (0.5%) related substances.

10. A process for preparing Form II olanzapine polymorph comprising slurrying technical grade olanzapine in ethyl acetate under anhydrous conditions and crystallizing Form II from the solution so formed.